Skip to main content

Table 1 Select characteristics of the study sample, overall and by race

From: Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype

Sociodemographic and clinical characteristics

Overall (N = 720), n (%)

Black (n = 540), n (%)

White (n = 159), n (%)

P value

Age at diagnosis (years), mean ± SD

52.6 ± 10.8

52.6 ± 11.0

52.3 ± 10.1

0.75

Age at diagnosis (years)

   

0.46

 20–45

200 (32.3)

148 (31.1)

52 (35.9)

 

 45–59

231 (37.3)

177 (37.3)

54 (37.2)

 

 ≥ 60

189 (30.5)

150 (31.6)

39 (26.9)

 

Menopausal status

   

0.07

 Premenopausal

325 (46.5)

241 (44.6)

84 (52.8)

 

 Postmenopausal

374 (53.5)

299 (55.4)

75 (47.2)

 

Race

    

 Black/African American

540 (77.2)

–

–

 

 White

159 (22.8)

–

–

 

Body mass index (kg/m2), mean ± SD

30.7 ± 7.0

31.6 ± 6.9

27.6 ± 6.5

< 0.0001

Body mass index (kg/m2)

   

< 0.0001

 18.5–24.99

177 (24.6)

88 (16.3)

68 (42.8)

 

 25.0–29.99

201 (27.9)

160 (29.6)

41 (25.8)

 

 30.0–34.99

176 (24.4)

147 (27.2)

29 (18.2)

 

 ≥ 35.0

166 (23.1)

145 (26.9)

21 (13.2)

 

Breast tumor clinicopathologic features

 Tumor grade

   

< 0.0001

  Well differentiated

107 (16.9)

66 (14.1)

33 (22.6)

 

  Moderately differentiated

218 (34.4)

148 (31.7)

65 (44.5)

 

  Poorly differentiated

309 (48.7)

253 (54.2)

48 (32.9)

 

 Tumor size

   

0.36

  < 1.0 cm

147 (20.4)

113 (20.9)

33 (20.8)

 

  1.0–2.0 cm

281 (39.0)

203 (37.6)

69 (43.4)

 

  > 2.0 cm

292 (40.6)

224 (41.5)

57 (35.8)

 

 AJCC stage

   

0.07

  Stage 0

61 (8.8)

52 (10.1)

9 (5.7)

 

  Stage I

256 (37.1)

177 (34.5)

70 (44.6)

 

  Stage II

271 (39.3)

204 (39.8)

60 (38.2)

 

  Stage III

96 (13.9)

77 (15.0)

16 (10.2)

 

  Stage IV

6 (0.9)

3 (0.6)

2 (1.3)

 

 Lymph node status

   

0.38

  Negative

406 (60.4)

298 (59.7)

98 (63.6)

 

  Positive

266 (39.6)

201 (40.3)

56 (36.4)

 

 Ki67 statusa

   

0.26

  Ki67−/favorable

348 (69.2)

272 (68.2)

69 (74.2)

 

  Ki67+/unfavorable

155 (30.8)

127 (31.8)

24 (25.8)

 

 ER status

   

0.01

  ER−

215 (29.9)

175 (32.5)

35 (22.0)

 

  ER+

503 (70.1)

363 (67.5)

124 (78.0)

 

 PR status

   

0.03

  PR−

333 (46.3)

260 (48.2)

64 (40.3)

 

  PR+

386 (53.7)

279 (51.8)

95 (59.7)

 

 HER2 status

   

0.59

  HER2−

573 (81.5)

429 (81.6)

125 (79.6)

 

  HER2+

133 (18.5)

97 (18.4)

32 (20.4)

 

 Breast cancer subtypeb

   

0.03

  Luminal A

420 (59.8)

300 (57.1)

104 (66.2)

 

  Luminal B

60 (8.6)

46 (8.8)

14 (8.9)

 

  HER2-E

70 (10.0)

51 (9.7)

18 (11.5)

 

  TN

152 (21.6)

128 (24.4)

21 (13.4)

 
  1. Race was missing or unknown among 21 (2.9%) participants
  2. aKi67 status was missing or unknown among 217 (30.1%) participants
  3. bBreast cancer subtypes were classified based on IHC expression of ER and PR, and overexpression or amplification of HER2 (by IHC or FISH) as reported in pathology records
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us